reports
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of August 2024 DENVER, Sept. 17, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of August 31, 2024, was $21.99. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended August 31, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market un...
ArrowMark Financial Corp. Announces Q2 2024 Results and Cash Distribut...
ArrowMark Financial Corp. Announces Q2 2024 Results and Cash Distribution of $0.45 per Share for the Third Quarter 2024 DENVER, Sept. 16, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial" or the “Fund”), an SEC registered closed-end management investment company, today announced that its Board of Directors has declared a cash distribution of $0.45 per share for the third quarter 2024. The distribution of $0.45 per share will be payable on September 30, 2024 to shareholders of record on September 26, 2024. “We are very pleased to announce net income...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of July 2024 DENVER, Aug. 14, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of July 31, 2024, was $21.75. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended July 31, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market u...
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Result...
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) programEarly indication of monotherapy activity in CTLA-4 ETB (MT-8421) program through T-reg depletion; no drug-related adverse events > grade 2Novel mechanism of action targeting CD38+ immune cells of B-cell, T-cell, and monocytic lineage representing enhanced potency in I&I without the need for conditioning therapy AUSTIN, Texas, Aug...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of June 2024 DENVER, July 11, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of June 30, 2024, was $21.58. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended June 30, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of May 2024 DENVER, June 18, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of May 31, 2024, was $21.76. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended May 31, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the sy...
ArrowMark Financial Corp. Announces Q1 2024 Results and Cash Distribut...
ArrowMark Financial Corp. Announces Q1 2024 Results and Cash Distribution of $0.45 per Share for the Second Quarter 2024 DENVER, June 14, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp. (Nasdaq: BANX) ("ArrowMark Financial" or the "Company"), an SEC registered closed-end management investment company, today announced that its Board of Directors has declared a cash distribution of $0.45 per share for the second quarter 2024. The total distribution of $0.45 per share will be payable on June 28, 2024 to shareholders of record on June 24, 2024. “We are very pleased to announce the net inc...
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. Provides Interim Update Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases. AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or “ETBs”) fo...
Molecular Templates, Inc. Reports First Quarter 2024 Financial Result...
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024. Recent Company Highlights MTEM presented clinical d...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of April 2024 DENVER, May 13, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of April 30, 2024, was $21.49. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended April 30, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under t...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of March 2024 DENVER, April 15, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of March 28, 2024, was $21.24. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended March 28, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under...
Molecular Templates Presents Interim Data from MT-6402 Phase I Study i...
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Result...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023. Company Highlights Durable si...
Molecular Templates Announces $9.5 Million Private Placement Offering ...
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced today it has entered into a definitive amended and restated secu...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of February 2024 DENVER, March 18, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of February 29, 2024, was $21.50. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended February 29, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Mar...
ArrowMark Financial Corp. Announces Q4 2023 Results and Cash Distribut...
ArrowMark Financial Corp. Announces Q4 2023 Results and Cash Distribution of $0.45 per Share for the First Quarter 2024 DENVER, March 06, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp. (Nasdaq: BANX) ("ArrowMark Financial" or the "Company"), an SEC registered closed-end management investment company, today announced that its Board of Directors has declared a cash distribution of $0.45 per share for the first quarter 2024. The total distribution of $0.45 per share will be payable on March 28, 2024 to shareholders of record on March 21, 2024. “We are very pleased to announce the net in...
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. Provides Interim Update Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, toda...
Arrowmark Financial Corp. Releases Month End Estimated Net Asset Value...
Arrowmark Financial Corp. Releases Month End Estimated Net Asset Value as of January 2024 DENVER, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of January 31, 2024, was $21.32. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended January 31, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market ...
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare L...
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference. Oppenheimer 34rd Annual Healthcare Conference, February 13 – 14 Format: Virtual PresentationDate: Wednesday, February 14, 2024Time: ...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of December 2023 DENVER, Jan. 16, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of December 31, 2023, was $21.43. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended December 31, 2023. We advise you that our audited NAV for December 31, 2023, will be released once we complete our annual report and may differ materially from this estima...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.